E
Eikon Therapeutics
Pioneering a new method of drug discovery based on tracking and measuring movement of individual proteins in live cells
At a glance
- Status
- Listed
- Listing
- IPO 2026
Open roles
Eikon Therapeutics in the Hayward ecosystem
The Eikon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A3 investors entered at this stage
Innovation Endeavors- TGThe Column Group
Foresite Capital
Series B and later20 investors entered at this stage
- HGHarel Group
- TIThe Howard Hughes Medical Institute
General Catalyst
CPP Investments- SMSoros Fund Management
- AIAlexandria Venture Investments
- EVE15 VC
Horizons Ventures- UIUC Investments
- AAAbu Dhabi Investment Authority
- HEHartford HealthCare Endowment
- ECEcoR1 Capital
- JAJanelia
AME Cloud Ventures
StepStone Group- SMSoros Capital Management
- SCSchroders
T. Rowe Price- UCUniversity of California
- BEBerkeley
Ownership
Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).
Source: Dealroom Talent Intelligence.
Patents
58 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Eikon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Eikon Therapeutics wins FDA clearance for Phase 1/2 trial of prostate cancer candidate EIK1006


